Exagen Inc. has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of experience in the life sciences industry, having held leadership roles in various medical technology companies. His previous positions include President and CEO of Silk Road Medical and Apollo Endosurgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.